A natural killer T cell nanoagonist-initiated immune cascade for hepatocellular carcinoma synergistic immunotherapy-Reference-Cited by-同舟云学术

A natural killer T cell nanoagonist-initiated immune cascade for hepatocellular carcinoma synergistic immunotherapy

Published:2024 Issue:23 Volume:16 Page:11126-11137
ISSN:2040-3364
Container-title:Nanoscale
language:en
Short-container-title:Nanoscale

Author:

Luo Ting¹²³,Tan Xiaoqiong³,Qing Guangchao³,Yu Jie²,Liang Xing-Jie³⁴^ORCID,Liang Ping¹²^ORCID

Affiliation:

1. School of Medicine, Nankai University, Tianjin, 300071, China

2. Department of Interventional Ultrasound, Fifth Medical Center of Chinese People's Liberation Army General Hospital, Beijing, 100853, China

3. CAS Key Laboratory for Biomedical Effects of Nanomaterials and Nanosafety, CAS Center for Excellence in Nanoscience, National Center for Nanoscience and Technology of China, Beijing, 100190, China

4. University of Chinese Academy of Sciences, Beijing 100049, China

Abstract

The hyaluronic acid modified zeolitic imidazolate framework-8 encapsulating α-galactosylceramide and doxorubicin, can effectively trigger NKT cell-mediated immune responses along with antitumor chemotoxicity.

Funder

National Basic Research Program of China

National Natural Science Foundation of China

Chinese Academy of Sciences

Publisher

Royal Society of Chemistry (RSC)

Link

http://pubs.rsc.org/en/content/articlepdf/2024/NR/D4NR00847B

Reference30 articles.

1. Cancer statistics, 2023

2. Management of Hepatocellular Carcinoma

3. BCLC strategy for prognosis prediction and treatment recommendation: The 2022 update

4. Camrelizumab versus placebo in combination with gemcitabine and cisplatin as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma (CAPTAIN-1st): a multicentre, randomised, double-blind, phase 3 trial

5. Immune checkpoint inhibitors in HCC: Cellular, molecular and systemic data